Triamcinolone
Triamcinolone is a synthetic intermediate-to-long-acting glucocorticoid, roughly five times as potent as cortisol, used heavily as a depot intra-articular and intramuscular injection (triamcinolone acetonide) and in topical/inhaled forms. In sport and recovery it is one of the most common joint-injection corticosteroids — effective for localised inflammation but chondrotoxic on repeat use and systemically suppressive from depot absorption.
01 Overview
Triamcinolone acetonide forms a long-lasting depot, giving weeks of local anti-inflammatory effect after a single joint or soft-tissue injection. This makes it popular for tendinopathy, bursitis and arthritis flares. Topical triamcinolone is a mainstay for inflammatory skin disease and the acetonide is also used in dental pastes and nasal sprays.
Despite being 'local', depot triamcinolone is absorbed systemically enough to suppress the HPA axis for weeks and to raise blood glucose transiently. Repeated intra-articular injections carry the same cartilage-harm concern as other corticosteroids. WADA prohibits injectable triamcinolone in-competition.
02 Mechanism
Glucocorticoid receptor agonist; the acetonide ester forms a poorly soluble depot for prolonged local anti-inflammatory action.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Topical | 0.025–0.5 % | Transdermal | Topical cream/ointment strengths for inflammatory skin disease. |
| Depot IM | 40–80 mg | IM | Systemic depot; a single dose can act for several weeks. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Prolonged local anti-inflammatory actionDepot injection quiets joint, tendon or bursal inflammation for weeks. | weeks per injection | Clinical | |
| Skin inflammation controlEffective for eczema, psoriasis and other inflammatory dermatoses. | topical | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPA axis suppression from depotSystemic absorption from depot injection suppresses adrenal cortisol for weeks. | Moderate | Common after depot | Clinical | |
| Injection-site atrophy / depigmentationLocal subcutaneous fat atrophy and skin depigmentation at superficial injection sites. | Moderate | Uncommon | Clinical | |
| Cartilage damage (repeat joint injection)Repeated intra-articular corticosteroid linked to cartilage loss. | Moderate | With repeated injections | Clinical |